
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is well-positioned in the rare kidney disease market with its flagship product, Filspari, showing strong demand in both the IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) indications. The recent approval of Voyxact, a competitor drug in the same market, is not expected to displace Filspari, but rather add to the overall market and potential synergies with Filspari. The extension of our Filspari IgAN exclusivity to October 2037, as well as the potential for a similar extension for FSGS, address key concerns from bears and significantly increase the net present value of our model. Given the strength of the product and its potential for continued growth, we maintain our positive outlook and Outperform rating on Travere Therapeutics' stock.
Bears say
Travere Therapeutics is currently facing multiple negative catalysts, including potential failures in upcoming earnings, ongoing legal struggles surrounding their flagship product Filspari, and potential competition from larger companies such as AZN, NVS, and VRTX in the rare-nephrology space. Additionally, the company's sole reliance on Filspari for revenue may pose a risk if the drug fails to meet expectations. These factors, coupled with high financial expectations and an uncertain pipeline with a Phase 3 drug expected in 2027, lead to a negative outlook on the stock's future performance.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares